KLK3 and Familial prostate cancer: Post-translational modifications of proteins, mainly aberrant glycosylation [5], represent a promising biomarker, potentially integrating both of these specificities with a typical tissue-specific marker—PSA (prostate-specific antigen) in the case of prostate cancer (PCa) [6,7].